BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 12507288)

  • 21. Early-stage idiopathic (primary) myelofibrosis--current issues of diagnostic features.
    Thiele J; Kvasnicka HM; Zankovich R; Diehl V
    Leuk Lymphoma; 2002 May; 43(5):1035-41. PubMed ID: 12148883
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinicopathological diagnosis and differential criteria of thrombocythemias in various myeloproliferative disorders by histopathology, histochemistry and immunostaining from bone marrow biopsies.
    Thiele J; Kvasnicka HM; Diehl V; Fischer R; Michiels J
    Leuk Lymphoma; 1999 Apr; 33(3-4):207-18. PubMed ID: 10221501
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Myelofibrosis--what's in a name? Consensus on definition and EUMNET grading.
    Thiele J; Kvasnicka HM
    Pathobiology; 2007; 74(2):89-96. PubMed ID: 17587880
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Problems and pitfalls regarding WHO-defined diagnosis of early/prefibrotic primary myelofibrosis versus essential thrombocythemia.
    Barbui T; Thiele J; Vannucchi AM; Tefferi A
    Leukemia; 2013 Oct; 27(10):1953-8. PubMed ID: 23467025
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The value of bone marrow histology in differentiating between early stage Polycythemia vera and secondary (reactive) Polycythemias.
    Thiele J; Kvasnicka HM; Zankovich R; Diehl V
    Haematologica; 2001 Apr; 86(4):368-74. PubMed ID: 11325641
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Aberrant expression of transforming growth factor beta-1 (TGF beta-1) per se does not discriminate fibrotic from non-fibrotic chronic myeloproliferative disorders.
    Bock O; Loch G; Schade U; von Wasielewski R; Schlué J; Kreipe H
    J Pathol; 2005 Apr; 205(5):548-57. PubMed ID: 15726648
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Proposal for revised diagnostic criteria of essential thrombocythemia and polycythemia vera by the Thrombocythemia Vera Study Group.
    Michiels JJ; Juvonen E
    Semin Thromb Hemost; 1997; 23(4):339-47. PubMed ID: 9263350
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Follow-up studies with sequential bone marrow biopsies in chronic myeloid leukaemia and so-called primary (idiopathic) osteo-myelofibrosis. Evolution of histopathological lesions and clinical course in 40 patients.
    Thiele J; Simon KG; Fischer R; Zankovich R
    Pathol Res Pract; 1988 Aug; 183(4):434-45. PubMed ID: 3186544
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The impact of clinicopathological studies on staging and survival in essential thrombocythemia, chronic idiopathic myelofibrosis, and polycythemia rubra vera.
    Kvasnicka HM; Thiele J
    Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):362-71. PubMed ID: 16810612
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Thrombocytosis versus thrombocythemia--differential diagnosis of elevated platelet count].
    Thiele J; Kvasnicka HM
    Pathologe; 2000 Jan; 21(1):31-8. PubMed ID: 10663667
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [The morphology features of bone marrow in the prefibrotic-early primary myelofibrosis].
    Gong XB; Zhang XH; Lu XG; Tang QS; Gao X; Yang J
    Zhonghua Xue Ye Xue Za Zhi; 2012 Jan; 33(1):25-30. PubMed ID: 22575188
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Histochemistry and morphometry on bone marrow biopsies in chronic myeloproliferative disorders - aids to diagnosis and classification.
    Thiele J; Kvasnicka HM; Fischer R
    Ann Hematol; 1999 Nov; 78(11):495-506. PubMed ID: 10602893
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis.
    Barbui T; Thiele J; Vannucchi AM; Tefferi A
    Blood Cancer J; 2015 Aug; 5(8):e337. PubMed ID: 26832847
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Practical application and clinical impact of the WHO histopathological criteria on bone marrow biopsy for the diagnosis of essential thrombocythemia versus prefibrotic primary myelofibrosis.
    Brousseau M; Parot-Schinkel E; Moles MP; Boyer F; Hunault M; Rousselet MC
    Histopathology; 2010 May; 56(6):758-67. PubMed ID: 20546341
    [TBL] [Abstract][Full Text] [Related]  

  • 35. European Bone Marrow Working Group trial on reproducibility of World Health Organization criteria to discriminate essential thrombocythemia from prefibrotic primary myelofibrosis.
    Buhr T; Hebeda K; Kaloutsi V; Porwit A; Van der Walt J; Kreipe H
    Haematologica; 2012 Mar; 97(3):360-5. PubMed ID: 22058215
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Histological diagnosis of Ph-negative myeloproliferative neoplasia. An overview].
    Campr V
    Cesk Patol; 2011 Jul; 47(3):84-93. PubMed ID: 21887923
    [TBL] [Abstract][Full Text] [Related]  

  • 37. JAK2(V617F) allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis.
    Hussein K; Bock O; Theophile K; von Neuhoff N; Buhr T; Schlué J; Büsche G; Kreipe H
    Exp Hematol; 2009 Oct; 37(10):1186-1193.e7. PubMed ID: 19616600
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic significance of bone marrow reticulin fibres in idiopathic myelofibrosis: evaluation of clinicopathological parameters in a scoring system.
    Iványi JL; Mahunka M; Papp A; Kiss A; Telek B
    Haematologia (Budap); 1994; 26(2):75-86. PubMed ID: 7890265
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Classification and diagnosis of essential thrombocythemia].
    Kirito K
    Rinsho Byori; 2012 Jun; 60(6):553-9. PubMed ID: 22880233
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Myelofibrosis in chronic myeloproliferative disorders--dynamics and clinical impact.
    Thiele J; Kvasnicka HM
    Histol Histopathol; 2006 Dec; 21(12):1367-78. PubMed ID: 16977587
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.